Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

Guttman-Yassky Emma; Bissonnette Robert; Ungar Benjamin; Suarez-Farinas Mayte; Ardeleanu Marius; Esaki Hitokazu; Suprun Maria; Estrada Yeriel; Xu Hui; Peng Xiangyu; Silverberg Jonathan I.; Menter Alan; Krueger James G.; Zhang Rick; Chaudhry Usman; Swanson Brian; Graham Neil M. H.; Pirozzi Gianluca; Yancopoulos George D.; Hamilton Jennifer D. D.

首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

【24h】

Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

机译：Dupilumab逐渐改善了特应性皮炎患者的全身和皮肤异常

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Dupilumab is an IL-4 receptor a mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.

机译：背景：Dupilumab是IL-4受体的抑制IL-4和IL-13的抑制信号，2型驱动炎症的关键驱动器，如Atopic /过敏性疾病患者的疗效所证明。

著录项

来源
《The Journal of Allergy and Clinical Immunology》 |2019年第1期|共18页
作者
Guttman-Yassky Emma; Bissonnette Robert; Ungar Benjamin; Suarez-Farinas Mayte; Ardeleanu Marius; Esaki Hitokazu; Suprun Maria; Estrada Yeriel; Xu Hui; Peng Xiangyu; Silverberg Jonathan I.; Menter Alan; Krueger James G.; Zhang Rick; Chaudhry Usman; Swanson Brian; Graham Neil M. H.; Pirozzi Gianluca; Yancopoulos George D.; Hamilton Jennifer D. D.;
展开▼
作者单位

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Innovaderm Res Montreal PQ Canada;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Regeneron Pharmaceut Tarrytown NY USA;

Kyushu Univ Grad Sch Med Sci Dept Dermatol Fukuoka Fukuoka Japan;

Icahn Sch Med Mt Sinai Dept Populat Hlth Sci &

Policy New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Icahn Sch Med Mt Sinai Dept Dermatol New York NY 10029 USA;

Northwestern Univ Dept Dermatol Prevent Med &

Med Social Sci Feinberg Sch Med Chicago IL 60611;

Baylor Univ Med Ctr Dept Dermatol Dallas TX USA;

Rockefeller Univ Lab Invest Dermatol 1230 York Ave New York NY 10021 USA;

Regeneron Pharmaceut Tarrytown NY USA;

Regeneron Pharmaceut Tarrytown NY USA;

Sanofi Bridgewater NJ USA;

Regeneron Pharmaceut Tarrytown NY USA;

Sanofi Bridgewater NJ USA;

Regeneron Pharmaceut Tarrytown NY USA;

Regeneron Pharmaceut Tarrytown NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
Atopic dermatitis; IL-4 receptor a inhibition; dupilumab; transcriptome; gene expression; skin; type 2 inflammation; epidermal pathology;

机译：特应性皮炎;IL-4受体抑制;Dupilumab;转录组;基因表达;皮肤;2型炎症;表皮病理学;

相似文献

外文文献
中文文献
专利

1. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis [J] . Guttman-Yassky Emma, Bissonnette Robert, Ungar Benjamin, The Journal of Allergy and Clinical Immunology . 2019,第1期

机译：Dupilumab逐渐改善了特应性皮炎患者的全身和皮肤异常
2. P479 Dupilumab improves patient-reported outcomes in atopic dermatitis patients inadequately controlled, intolerant, or inadvisable for cyclosporine-A [J] . M. De Bruin-Weller, A. Gadkari, E. Simpson, Annals of allergy, asthma, and immunology . 2017,第5期

机译：P479 Dupilumab改善了患者报告的特应性皮炎患者的结果不足，不耐受，或不可于环孢菌素-A
3. DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN ATOPIC DERMATITIS PATIENTS INADEQUATELY CONTROLLED, INTOLERANT, OR INADVISABLE FOR CYCLOSPORINE-A [J] . De Bruin-Weller M., Gadkari A., Simpson E., Annals of allergy, asthma, and immunology . 2017,第5Suppla1期

机译：Dupilumab改善了患者报告的特应性皮炎患者的结果不充分控制，不耐受，或不可于环孢菌素-A
4. Clinical Improvement and Immunological Changes of Atopic Dermatitis in Patients Undergoing Subcutaneous Immunotherapy with Depigmented Polymerized House Dust Mite Allergens [C] . C. Bussmann, AJ. Hart, S. Vrtala, Collegium Internationale Allergologicum . 2007

机译：用沉淀聚合房屋粉尘螨过敏原患者检查患者特应性皮炎的临床改善和免疫变化
5. Genetic determinants of Staphylococcus aureus colonization in Atopic Dermatitis patients. [D] . Yeung, Melinda K. 2008

机译：特应性皮炎患者中金黄色葡萄球菌定植的遗传决定因素。
6. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized Controlled Phase 3 Clinical Trials [O] . Eric L. Simpson 2017

机译：Dupilumab改善中度至重度特应性皮炎患者的一般健康相关生活质量：两项随机对照三期临床试验的汇总结果
7. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis [O] . Emma Guttman-Yassky, Robert Bissonnette, Benjamin Ungar, 2019

机译：Dupilumab逐渐改善了特应性皮炎患者的全身和皮肤异常

Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

摘要

著录项

相似文献

相关主题

期刊订阅